Tuesday, June 15, 2021 : Issue #1141 |
|
Letter from the Editor
 Before Amylin hit it big with Byetta and Bydureon, and their employees and stock holders were well rewarded with their eventual purchase by BMS and AZ, they had another product that many of us thought would be a big hit. You may remember a product called SYMLIN® (pramlintide acetate) that is an analog of the pancreatic hormone amylin that the company took their name from.
This drug looked to be a great product for both type 1 and type 2 patients, and had some of the same great qualities found in the GLP-1 analog class, but it needed multiple daily injections and it never really caught on with the type 1 crowd. As the success of the GLP-’s grew the use of pramlintide almost disappeared.
This week our intern, George McConnell, PharmD. Candidate, LECOM School of Pharmacy, takes a look at a possible new way to deliver pramlintide, and how valuable it can be for type 1 patients, especially if they are on a closed loop system.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
